Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

Browse Trials

Currently viewing trials
(Last updated: February 22, 2020)

Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
Close
Treatment

BRCA1/2

Chemotherapy

Hormone Therapy

Radiation Oncology

Surgery

Surgery: Reconstruction

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Alternative Medicine

Decision Support

Diagnosing Breast Cancer

Genetics/Family History

Having Children

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Preventing Breast Cancer

Preventing Recurrence

Screening

Support/Education

Surveys/Interviews/Registries

1

NEAREST SITE: 353 miles
City of Hope National Medical Center
Duarte,CA

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT03199586

NP-G2-044 in Patients With Advanced Breast Cancer

First-in-Human, Dose Finding, Open Label Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) Scientific Title

Purpose
To study the safety and best dose of an experimental targeted therapy called NP-G2-044 that binds to a protein called fascin.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer that is no longer responding to standard treatment.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NP-G2-044, by mouth, daily (1 month on, 2 weeks off), ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study is investigating the safety and best dose of an experimental targeted therapy called NP-G2-044 that binds to a protein called fascin. </li> <li class="seamTextUnorderedListItem">This study is also enrolling people with other types of advanced and metastatic cancers.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03199586' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/cancer-care/clinical-trials/18-051' target='_blank'>Memorial Sloan Kettering Cancer Center: Study Website</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/793138' target='_blank'>NCI Drug Dictionary: Fascin Inhibitor NP-G2-044</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/medgen/1633753' target='_blank'>MedGen: Fascin Inhibitor NP-G2-044</a> </li></ul>
See more